BioWorld Asia

June 15, 2011

4SC Stock Plummets on Vidofludimus Miss in RA

Shares in 4SC AG dropped 36 percent June 8 on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb trial in rheumatoid arthritis, dashing investor hopes of a near-term deal. (BioWorld International) Read More

Ipsen Restructures to Focus on Peptides and Toxins

Heart Stem Cells Can Make New Muscle, Study Shows

Quintiles Takes Equity Stake in Kareus Therapeutics

New Leadership Takes Over at Embattled Agency

UK Government Funds Tumor Profiling Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...